Compare Marsh & McLennan Companies, Inc. (MRSH) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Xylem, Inc. — how do they compare? Marsh & McLennan Companies, Inc. trades at $180.04 (market cap $87.77B), while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 3.1× Xylem, Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.17%). Which is the better fit depends on your goals.
| MRSH | XYL | |
|---|---|---|
Market Cap | $87.77B | $28.67B |
Sector | Financials | Industrials |
52-Week High | $211.21 | $152.95 |
52-Week Low | $157.32 | $106.34 |
Enterprise Value | $108.61B | $29.92B |
Dividend Yield | 2.17% | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $181.59, down 0.32% on the day, with a bullish technical signal from moving averages and support at $180. The company reported strong Q2 2026 earnings, beating estimates with $2.96 EPS versus $2.88 expected, driven by 6% revenue growth to $7.4 billion. Fundamentals show robust profitability with a 14.26% net margin and 27.42% ROE, while valuation ratios like P/E of 22.77 and P/S of 3.26 reflect premium pricing. Recent news highlights a 10% dividend increase to $0.99 per share, payable in August 2026.
The outlook for MRSH is positive, supported by consistent earnings beats and strategic AI investments, but risks include rising operating expenses and softer insurance pricing. Analysts maintain a consensus price target of $203.75, implying 12% upside, with 11 buy ratings outweighing 1 sell. Investors should monitor expense management and organic growth sustainability amid competitive pressures.
XYL trades at $117.00, down 4.71% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. Fundamentally, the company shows steady revenue growth from $8.6B in 2024 to $9.04B in 2025, with net income margins improving to 10.79%. Recent earnings beats and a consistent dividend history support investor confidence, while analyst consensus leans slightly bullish with a $152.71 price target.
The outlook for XYL remains positive given its earnings momentum and strategic partnerships in water technology. Key risks include execution challenges in integrating new leadership and macroeconomic pressures on industrial spending. The stock offers potential upside to analyst targets but requires monitoring of upcoming Q2 2026 results due July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
